Last reviewed · How we verify
NCT05652855
Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors
Phase 1, PHASE2 trial testing MHB088C for Injection in Advanced or Metastatic Solid Tumors in 48 participants. Not yet recruiting.
31 January 2026
Quick facts
| Lead sponsor | Minghui Pharmaceutical Pty Ltd |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 23 January 2023 |
| Primary completion | 31 January 2026 |
| Estimated completion | 31 July 2026 |
| Sites | 3 locations across Australia |
Drugs / interventions tested
- MHB088C for Injection — full drug profile →
Conditions studied
- Advanced or Metastatic Solid Tumors — all drugs for Advanced or Metastatic Solid Tumors →
Sponsor
Minghui Pharmaceutical Pty Ltd — full company profile →
Who can join
18 and older, any sex, with Advanced or Metastatic Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the safety/tolerability, pharmacokinetics and efficacy of MHB088C in participants with advanced or metastatic solid tumors.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Antibody drug conjugates in the clinic.
Udofa E, Sankholkar D, Mitragotri S, Zhao Z. · · 2024 · cited 12× · PMID 39545074 · DOI 10.1002/btm2.10677 -
Advancements in antibody-drug conjugates as cancer therapeutics.
Fong JY, Phuna Z, Chong DY, Heryanto CM, et al · · 2025 · cited 11× · PMID 40814440 · DOI 10.1016/j.jncc.2025.01.007 -
Research progress of B7-H3 in malignant tumors.
Zhao S, Zhang H, Shang G. · · 2025 · cited 6× · PMID 40519928 · DOI 10.3389/fimmu.2025.1586759 -
Unlocking New Horizons: Antibody-Drug Conjugates in Small Cell Lung Cancer.
Liu J, Cui Y, Liao D, Sima M, et al · · 2025 · PMID 41463450 · DOI 10.3390/biology14121677 -
What Is On the Horizon for the Diagnosis and Treatment of SCLC and Large Cell Neuroendocrine Cancer?
Lim SM, Shim JSG, Shim HS, Tanizaki J, et al · · 2025 · PMID 41041628 · DOI 10.1016/j.jtocrr.2025.100871 -
Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment.
Marchesi S, Marinello A, Ambrosini P, Cavalli C, et al · · 2025 · PMID 40603576 · DOI 10.1038/s41698-025-01011-7
Verify or expand the search:
- PubMed search for NCT05652855
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced or Metastatic Solid Tumors
Currently open trials in the same condition.
- NCT07510828 — PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07205718 — A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07260305 — A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolima · Phase 1 · recruiting
- NCT06548217 — A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting
- NCT05957081 — Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 · Phase 1 · recruiting
Other Minghui Pharmaceutical Pty Ltd trials
Trials by the same sponsor.
- NCT05642949 — Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors · Phase 1, PHASE2 · not yet recruiting
- NCT04815148 — MH004 Topical Cream in Healthy Adult Volunteers and Participants With Atopic Dermatitis or Rheumatoid Arthritis · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05652855 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Minghui Pharmaceutical Pty Ltd
- Last refreshed: 9 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05652855.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing